488 related articles for article (PubMed ID: 1722483)
1. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
4. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma.
Fujiyama S; Morishita T; Hashiguchi O; Sato T
Cancer; 1988 Apr; 61(8):1621-8. PubMed ID: 2450634
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
8. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.
Fujiyama S; Izuno K; Yamasaki K; Sato T; Taketa K
Tumour Biol; 1992; 13(5-6):316-23. PubMed ID: 1283927
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
10. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
11. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
[TBL] [Abstract][Full Text] [Related]
12. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma.
Fujiyama S; Izuno K; Gohshi K; Shibata J; Sato T
Dig Dis Sci; 1991 Dec; 36(12):1787-92. PubMed ID: 1721019
[TBL] [Abstract][Full Text] [Related]
14. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
Sassa T; Kumada T; Nakano S; Uematsu T
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
[TBL] [Abstract][Full Text] [Related]
19. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
20. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
